Novartis gets Bexsero OK in Australia; Natco boosted by exports; AMA rails at docs for using angioplasty when drugs would do;

@FiercePharma: New data cuts link between preventive use of Propecia/Proscar and faster-growing prostate tumors. More | Follow @FiercePharma

@CarlyHFierce: South Africa's Adcock Ingram so far staying true to suitor CFR - still in exclusive talks after $1.3B bid. Report | Follow @CarlyHFierce

> Novartis ($NVS) has gotten approval in Australia for its meningococcal B vaccine Bexsero for patients from two months of age and older. Release

> India's Natco Pharma reported a 27.6% jump in net profit in the last quarter, powered by exports. Story

> A new study says about 20% of neurologists were unaware of the risks of certain anti-epilepsy drugs and faults the FDA for not doing a better job of communicating them. Report

> A former Takeda manager who has lost two rounds in his whistleblower lawsuit tied to Kapidex marketing is asking that the U.S. Supreme Court review a lower court ruling that restricts whistleblower complaints. Report

> Celgene ($CELG) has launched Imnovid (pomalidomide), its new oral blood cancer drug, in the U.K. and Ireland to be used by patients as a third-line treatment for multiple myeloma. Story

Medical Device News

@FierceMedDev: Special Report: How did Israel become a hotbed for medical devices? Feature | Follow @FierceMedDev

@DamianFierce: FDA's former IT boss Eric Perakslis nails down industry gig. Story from FierceBiotechIT.com | Follow @DamianFierce

@MarkHFierce: Second Sight achieved the holy grail for new devices: CMS reimbursement. Press release | Follow @MarkHFierce

@MichaelGFierce: St. Jude nets FDA approval for low-radiation ablation catheters. News | Follow @MichaelGFierce

> NxThera to launch U.S. clinical trial with $18.2M Series C. More

> Medtronic closes in on FDA nod with drug-eluting balloon. Article

> Study: Spooked docs are lining Dx companies' pockets. Story

> InSightec's surgery-free brain tech eases tremor in study. Report

Biotech News

@FierceBiotech: ICYMI yesterday: The hottest disease field for biotech startups and M&A might surprise you (not cancer). Article | Follow @FierceBiotech

@JohnCFierce: Two biotechs--Alexion and Regeneron--in top 5 of Forbes' top 100 innovators. Impressive. Article | Follow @JohnCFierce

@RyanMFierce: ICYMI: The man who cured aging? Industry Voices | Follow @RyanMFierce

@EmilyMFierce: Seattle BioMed wins $16M NIH grant for tuberculosis research. Article | Follow @EmilyMFierce

> Forest, Almirall combo COPD drug stumbles as Big Pharma rivals race ahead. Story

> M&A watch: Amgen and Onyx haggle over Kyprolis data in stalled buyout talks. Report

> Biotech dealmaking pace slows, but PhII remains popular. Article

Pharma Manufacturing News

@EricPFierce: Not all of the Merck plants in Ireland have seen jobs cut. A plant in Swords added 70 people last year. Report | Follow @EricPFierce

> Deaths tied to recalled drugs from Texas compounder. More

> Jubilant HollisterStier adds to global sterile manufacturing supply. Report

> FDA takes deep dive into opioid APIs. More

> Sanofi U.K. plant benefits from SkyePharma progress. Article

> Deaths tied to recalled drugs from Texas compounder. Story

Vaccines News

> Vaccine calms fears of meningitis becoming AIDS-like epidemic. More

> Researchers aim at trial to test whether BCG vaccine cuts risk of allergies. Report

> Study reconfirms safety of flu vaccine in pregnant women. Story

> Researchers aim at trial to test whether BCG vaccine cuts risk of allergies. More

> Incredulity turns to praise as malaria vaccine posts positive PhI data. Article

And Finally... A recent report by the American Medical Association (AMA) and the Joint Commission says that doctors are still too often using elective angioplasty, the procedure recently performed on former president George W. Bush, on patients with coronary disease who could be treated successfully with drugs alone. Story

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.